Provera

Provera essentials: key product information

Provera, containing the active ingredient medroxyprogesterone acetate, is a synthetic progestogen medication licensed for hormone-related conditions in the United Kingdom. It plays a significant role in managing gynaecological disorders and is available on NHS prescription.

Pharmacological profile: how Provera works

The medication exerts its effects by binding to progesterone receptors in reproductive tissues. This binding alters the endometrial lining, preventing excessive tissue growth and stabilising uterine function. Following oral administration, peak blood concentrations typically occur within 2-4 hours before undergoing hepatic metabolism, with renal excretion completing the elimination process.

Several important pharmacological interactions require consideration:

• Avoid concurrent use with St. John's Wort due to potential efficacy reduction
• Exercise caution with CYP3A4 inducers like carbamazepine and rifampicin
• Monitor closely when combined with protease inhibitors or antifungal medications

Licensed uses

In the UK, Provera is licensed for:

• Management of abnormal uterine bleeding patterns
• Treatment of secondary amenorrhoea (absent menstrual periods)
• Endometrial hyperplasia prevention in postmenopausal women using oestrogen therapy

Provera is also used for:

• Mild to moderate endometriosis
• Certain hormone-dependent cancers, such as advanced breast cancer (higher-strength tablets)

Special population considerations include strict contraindication during pregnancy due to potential fetal harm risks. Elderly patients require careful thrombosis risk assessment before initiation. Provera should be avoided in those with undiagnosed vaginal bleeding or certain cancers involving hormone-sensitive tissues.

Provera dosing protocols

Provera should not be used in patients with severe liver impairment. Tablets should be stored below 25°C away from moisture, while injectable formulations must be protected from freezing temperatures.

Take doses at consistent times each day. Should tablets be forgotten, patients should take the missed dose when remembered unless approaching the next scheduled dose. Blood investigations may be recommended periodically to assess ongoing suitability.

Provera critical safety considerations

Before taking Provera (medroxyprogesterone acetate), patients must understand its contraindications and safety profile. This medication is unsuitable for individuals with active thrombosis history, undiagnosed vaginal bleeding, or liver disease due to metabolic pathways.

Common adverse effects include weight changes, headache and nausea. Notably, injectable formulations carry additional concerns - long-term injections correlate with bone density reduction, particularly after two years of continuous use. Thrombosis remains a rare but serious risk, necessitating vigilance toward symptoms like leg pain or breathing difficulties.

Prescription decisions involve comprehensive evaluation of personal thrombosis risk factors, skeletal health, and liver function. Medical professionals balance therapeutic benefits against potential harm before approving treatment. Documentation of bone density changes remains essential for injectable users.

Provera treatment alternatives comparison

Norethisterone is often preferred for short-term bleeding control. Injectable medroxyprogesterone (Depo-Provera) avoids daily compliance barriers but display different pharmacokinetic profiles. Decision factors involve bleeding patterns, contraindications, and convenience needs.

Micronised progesterone is often preferred for long-term HRT because of its more favourable risk profile.

Common patient questions about Provera

Patients frequently ask about Provera's impact on future fertility - particularly whether it causes permanent infertility. Healthcare providers emphasise it doesn't cause permanent infertility. Alcohol interactions constitute another common concern due to Provera's hepatic metabolism pathways. Current evidence shows limited clinical interaction data between medroxyprogesterone acetate and alcohol. Nevertheless, caution remains advisable given individual metabolic variations. Many queries involve menstrual pattern changes such as irregular spotting. This represents an expected physiological response during treatment initiation. Unexpected bleeding patterns after prolonged amenorrhoea, however, warrant medical review. Patients often ask about weight fluctuation potential. Some individuals experience modest weight changes requiring dietary monitoring. Others query appropriate timeline expectations for resolving abnormal uterine bleeding - typically ranging between three to six months under proper medical supervision.

Guidelines for proper use of Provera

Optimal medication management follows specific administration protocols. Take tablets at consistent daily intervals to maintain therapeutic levels. Food does not significantly impact absorption. Several consumption precautions apply:

• Drug interactions: Avoid grapefruit products due to CYP450 enzyme interference affecting metabolism
• Alcohol moderation: Limit consumption considering hepatic processing pathways
• Storage conditions: Keep tablets at room temperature away from moisture; promptly discard discoloured tablets

Critical safety measures include never doubling doses after missed tablets - simply resume normal scheduling. Report persistent unexpected bleeding or amenorrhoea exceeding expected timeframes. Patients should cross-reference medication leaflets with GP consultations - particularly regarding screening requirements before long-term contraceptive use. Pharmacy teams provide counselling on potential mood changes warranting medical review. Regulated pharmacies, including online pharmacies, supply Provera only against a valid prescription. Proper disposal involves returning unused portions to community pharmacies under the UK medicines take-back scheme rather than household waste systems.